Your browser doesn't support javascript.
loading
Would You Recommend a Statin to This Patient for Primary Prevention of Cardiovascular Disease? : Grand Rounds Discussion From Beth Israel Deaconess Medical Center.
Smetana, Gerald W; Benson, Mark D; Juraschek, Stephen P; Burns, Risa B.
Afiliação
  • Smetana GW; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (G.W.S., M.D.B., S.P.J., R.B.B.).
  • Benson MD; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (G.W.S., M.D.B., S.P.J., R.B.B.).
  • Juraschek SP; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (G.W.S., M.D.B., S.P.J., R.B.B.).
  • Burns RB; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts (G.W.S., M.D.B., S.P.J., R.B.B.).
Ann Intern Med ; 175(6): 862-872, 2022 06.
Article em En | MEDLINE | ID: mdl-35696686
Cardiovascular disease (CVD) is the leading cause of death in the United States. Hypercholesterolemia is a principal modifiable risk factor for the primary prevention of CVD. In addition to lifestyle modification, statins are an important tool to reduce risk for CVD in selected patients. A useful strategy to identify candidates for statins is to estimate the 10-year risk for CVD through the use of a validated risk calculator. Commonly used calculators include the Framingham risk score and the pooled cohort equation. Multiple randomized controlled trials have shown that statins reduce the risk for CVD in patients without known CVD. Two recent guidelines have proposed an approach to the use of statins in primary prevention of CVD. The American College of Cardiology/American Heart Association and the U.S. Department of Veterans Affairs guidelines form the basis for this discussion. The guidelines differ on the use of advanced testing to modify the 10-year CVD risk estimate and on the need for low-density lipoprotein cholesterol targets to establish the efficacy of statins. Advanced testing with coronary artery calcium measurement may be helpful for patients who are potentially eligible for statin therapy but who are uncertain if they wish to take a statin. In this paper, 2 experts, a preventive cardiologist and a general internist, discuss their approach to the use of statins for primary prevention of CVD and how they would apply the guidelines to an individual patient.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Visitas de Preceptoria Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Inibidores de Hidroximetilglutaril-CoA Redutases / Visitas de Preceptoria Tipo de estudo: Clinical_trials / Etiology_studies / Guideline / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Humans País como assunto: America do norte Idioma: En Ano de publicação: 2022 Tipo de documento: Article